This article first appeared on GuruFocus.
Parnassus Value Equity Fund (Trades, Portfolio) recently submitted its N-PORT filing for the first quarter of 2026, revealing strategic investment decisions made during this period. As part of Jerome Dodson (Trades, Portfolio)s Parnassus Investments, the fund is known for its fossil-fuel-free and positive workplace investment philosophy. Initially managed by Dodson, the fund transitioned to Billy Hwan’s leadership in 2020. In 2021, Affiliated Managers Group acquired a majority stake in Parnassus. Formerly the Parnassus Endeavor Fund, it was renamed on December 30, 2022. The fund focuses on U.S. large-cap companies with competitive advantages, quality management, and strong ESG performance, aiming to outperform the S&P 500 Index by investing in undervalued stocks.
Parnassus Value Equity Fund (Trades, Portfolio) added a total of two stocks, among them:
The most significant addition was AstraZeneca PLC (NYSE:AZN), with 634,492 shares, accounting for 2.73% of the portfolio and a total value of $125.13 million.
The second largest addition to the portfolio was Boston Scientific Corp (NYSE:BSX), consisting of 678,208 shares, representing approximately 0.93% of the portfolio, with a total value of $42.56 million.
Parnassus Value Equity Fund (Trades, Portfolio) also increased stakes in a total of 23 stocks, among them:
The most notable increase was JPMorgan Chase & Co (NYSE:JPM), with an additional 72,858 shares, bringing the total to 572,217 shares. This adjustment represents a significant 14.59% increase in share count, a 0.47% impact on the current portfolio, with a total value of $168.32 million.
The second largest increase was Waste Management Inc (NYSE:WM), with an additional 82,299 shares, bringing the total to 370,208. This adjustment represents a significant 28.59% increase in share count, with a total value of $85.07 million.
Parnassus Value Equity Fund (Trades, Portfolio) completely exited three holdings in the first quarter of 2026, as detailed below:
